All Stories

  1. Historical aspects of botulinum toxin used clinically: part II: overcoming resistance

    Article • The Botulinum J, January 2015, Inderscience Publishers

    Professor Andy M Pickett

  2. Counterfeit Botulinum Medical Products and the Risk of Bioterrorism

    Article • December 2014, Springer Science + Business Media

    Professor Andy M Pickett

  3. Counterfeit Botulinum Medical Products and Risk of Bioterrorism

    Article • January 2014, Springer Science + Business Media

    Professor Andy M Pickett

  4. Botulinum Toxin as a Clinical Product: Manufacture and Pharmacology

    Article • January 2014, Springer Science + Business Media

    Professor Andy M Pickett

  5. Reviews of botulinum toxin products in aesthetic use must be accurate, clear and avoid speculation

    Article • Clinical Pharmacology Advances and Applications, September 2013, Taylor & Francis

    Professor Andy M Pickett

  6. Historical aspects of botulinum toxin used clinically: Part I: is that the right serotype?

    Article • The Botulinum J, January 2013, Inderscience Publishers

    Professor Andy M Pickett

  7. Immunogenicity Issues Related to Botulinum Toxins in Clinical Use Cannot Be Answered by Speculation About Product Characteristics

    Article • BioDrugs, December 2012, Springer Science + Business Media

    Professor Andy M Pickett

  8. Inability of Speculation to Explain Dose Effect Differences Between Botulinum Toxin Products

    Article • Archives of Facial Plastic Surgery, November 2012, American Medical Association (AMA)

    Professor Andy M Pickett

  9. Advances in non-surgical facial aesthetics

    Article • Faculty Dental Journal, October 2012, Royal College of Surgeons of England

    Professor Andy M Pickett

  10. Animal Studies with Botulinum Toxins May Produce Misleading Results

    Article • Anesthesia & Analgesia, September 2012, Wolters Kluwer Health

    Professor Andy M Pickett

  11. Evaluating botulinum toxin products for clinical use requires accurate, complete, and unbiased data

    Article • Clinical Ophthalmology, September 2011, Taylor & Francis

    Professor Andy M Pickett

  12. Serious issues relating to counterfeit dermal fillers available from Internet sources

    Article • Journal of the American Academy of Dermatology, September 2011, Elsevier

    Professor Andy M Pickett

  13. Consistent Biochemical Data are Essential for Comparability of Botulinum Toxin Type A Products

    Article • Drugs in R&D, March 2011, Springer Science + Business Media

    Professor Andy M Pickett

  14. Consistent Biochemical Data are Essential for Comparability of Botulinum Toxin Type A Products

    Article • Drugs in R&D, March 2011, Springer Science + Business Media

    Professor Andy M Pickett

  15. New Trends in the Science of Botulinum Toxin-A as Applied in Dystonia

    Article • International Journal of Neuroscience, January 2011, Informa Healthcare

    Professor Andy M Pickett

  16. Towards New Uses of Botulinum Toxin as a Novel Therapeutic Tool

    Article • Toxins, January 2011, MDPI AG

    Professor Andy M Pickett

  17. Re-Engineering Clostridial Neurotoxins for the Treatment of Chronic Pain

    Article • BioDrugs, June 2010, Springer Science + Business Media

    Professor Andy M Pickett

  18. The Science and Manufacturing Behind Botulinum Neurotoxin Type A-ABO in Clinical Use

    Article • Aesthetic Surgery Journal, November 2009, Oxford University Press (OUP)

    Professor Andy M Pickett

  19. Dysport®: Pharmacological properties and factors that influence toxin action

    Article • Toxicon, October 2009, Elsevier

    Professor Andy M Pickett

  20. Serious issues relating to the clinical use of unlicensed botulinum toxin products

    Article • Journal of the American Academy of Dermatology, July 2009, Elsevier

    Professor Andy M Pickett

  21. Inappropriate Conclusions From the Use of Botulinum Toxin for the Treatment of Spasticity

    Article • Clinical Neuropharmacology, May 2009, Wolters Kluwer Health

    Professor Andy M Pickett

  22. Composition and Molecular Size of Clostridium botulinum Type A Toxin–Hemagglutinin Complex

    Article • Journal of Protein Chemistry, April 2009, Springer Science + Business Media

    Professor Andy M Pickett

  23. The in vivo rat muscle force model is a reliable and clinically relevant test of consistency among botulinum toxin preparations

    Article • Toxicon, September 2008, Elsevier

    Professor Andy M Pickett

  24. Counterfeit botulinum toxins—A serious risk to patient safety

    Article • Toxicon, June 2008, Elsevier

    Professor Andy M Pickett

  25. Migration of type A botulinum toxin in vivo is not related to the size of the toxin complex

    Article • Toxicon, June 2008, Elsevier

    Professor Andy M Pickett

  26. Development of a multi-step approach for the detection of neutralising antibodies to botulinum toxin Type A

    Article • Toxicon, June 2008, Elsevier

    Professor Andy M Pickett

  27. On the discovery of Bacillus botulinus

    Article • The Botulinum J, January 2008, Inderscience Publishers

    Professor Andy M Pickett

  28. Biochemical, functional and potency characteristics of type A botulinum toxin in clinical use

    Article • The Botulinum J, January 2008, Inderscience Publishers

    Professor Andy M Pickett

  29. Liquid Flow and Mixing in Concentric Tube Air‐Lift Reactors

    Article • Journal of Chemical Technology & Biotechnology, June 1996, Wiley

    Professor Andy M Pickett

  30. Liquid Flow and Mixing in Concentric Tube Air-Lift Reactors

    Article • Journal of Chemical Technology & Biotechnology, June 1996, Wiley

    Professor Andy M Pickett